IntelGenX enters into agreement with ATAI Life Sciences to develop novel formulations of pharmaceutical-grade psychedelics.
ATAI Life Sciences is preparing to add three new drug development partners as it builds the premier R&D platform in the psychedelics space.
Among publicly listed companies in the psychedelics space, most are psychedelics-cannabis hybrids. It actually makes a lot of sense.
MindMed's new President will be expanding the company's R&D footprint in Europe and leading Project Lucy.